FDA has removed the Risk Evaluation and Mitigation Strategy requirements for erythropoiesis-stimulating agents in patients with anemia due to associated myelo-suppressive chemotherapy.
Urologic oncologist Wayne Brisbane thought his patient might be a good candidate for focal therapy.
